Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial is a research paper published in The Lancet Microbe (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →University of Maryland
Grant: UM1 AI148689
BARDA
Grant: 75A50120D00017
NIAID NIH HHS
Grant: K08 AI143923
NIAID NIH HHS
Grant: K08 AI170950
NIAID
U.S. Department of Health and Human Services
Administration for Strategic Preparedness and Response
Fields of Study
MeSH Terms